(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 September 2008 (12.09.2008)

PCT

(10) International Publication Number
WO 2008/109440 A3

(51) International Patent Classification:
G01N 33/574 (2006.01) *A61K 39/395* (2006.01)
C12Q 1/68 (2006.01)

(21) International Application Number:
PCT/US2008/055502

(22) International Filing Date:
29 February 2008 (29.02.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/892,640	2 March 2007 (02.03.2007)	US
60/912,053	16 April 2007 (16.04.2007)	US
61/029,748	19 February 2008 (19.02.2008)	US

(71) Applicant *(for all designated States except US)*: **GENENTECH, INC.** [US/US]; 1 Dna Way, South San Francisco, CA 94080-4990 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **F.HOFFMAN-LA ROCHE, AG** [CH/CH]; Grenzacherstrasse 124, CH-4002 Basel (CH). **AMLER, Lukas, C.** [DE/US]; 845 Grenada Lane, Foster City, CA 94404 (US). **BIRKNER, Merrill** [US/US]; 160 Brannan Street, Apt. 404, San Francisco, CA 94107 (US). **LIN, Chin-Yu** [—/US]; 300 Baltic Circle, Unit 322, Redwood City, CA 94065 (US). **MOECKS, Joachim** [DE/DE]; Max-Joseph-Strasse 9, 68167 Mannheim (DE). **STRAUSS, Andreas** [DE/DE]; Ruhe Am Bach 5B, 82377 Penzberg (DE).

(74) Agents: **DREGER, Ginger, R.** et al.; Goodwin Procter LLP, 135 Commonwealth Drive, Menlo Park, CA 94025 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: PREDICTING RESPONSE TO A HER DIMERISATION INHIBITOR BASED ON LOW HER3 EXPRESSION




FIG. 6

(57) Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.

WO 2008/109440 A3

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
23 April 2009